Purpose: Case series reported 20-40% mortality rates for patients with Fournier's gangrene with some series as high as 88%. This literature comes almost exclusively from referral centers. Materials and Methods: We identified and analyzed inpatients with Fournier's gangrene who had a surgical debridement or died in the US State Inpatient Databases. Results: One thousand six hundred and forty one males and 39 females with Fournier's gangrene represented <0.02% of hospital admissions. Overall, the incidence was 1.6 cases per 100,000 males and case fatality was 7.5%. Sixty six percent of hospitals cared for no cases per year, 17% cared for 1 case per year, 10% cared for 2 cases per year, 4% cared for 3 cases per year, 1% cared for 4 cases per year, and only 1% cared for ≥5 cases per year. Teaching hospitals had higher mortality (adjusted OR 1.9) due primarily to more acutely ill patients. Hospitals treating more than 1 Fournier's gangrene case per year had an adjusted 42-84% lower mortality (p < 0.0001). Conclusions: Most hospitals rarely care for Fournier's gangrene patients. The population-based mortality rate (7.5%) was substantially lower than the case series from tertiary care centers. Hospitals that treated more number of Fournier's gangrene patients had lower mortality rates, thereby supporting the rationale that regionalized care worked well for patients with this rare disease.

Keywords:
Fournier’s gangrene, Mortality, Necrotizing infection, Epidemiology, Outcomes, Management
1.
Fournier JA: Gangrene foudroyante de la verge (overwhelming gangrene). Sem Med 1883;3:345.
2.
Basoglu M, Ozbey I, Atamanalp SS, Yildirgan MI, Aydinli B, Polat O, et al: Management of Fournier's gangrene: review of 45 cases. Surg Today 2007;37:558-563.
3.
Vick R, Carson CC 3rd: Fournier's disease. Urol Clin North Am 1999;26:841-849.
4.
Eke N: Fournier's gangrene: a review of 1726 cases. Br J Surg 2000;87:718-728.
5.
Endorf FW, Supple KG, Gamelli RL: The evolving characteristics and care of necrotizing soft-tissue infections. Burns 2005;31:269-273.
6.
Stone HH, Martin JD Jr: Synergistic necrotizing cellulitis. Ann Surg 1972;175:702-711.
7.
Carvalho JP, Hazan A, Cavalcanti AG, Favorito LA: Relation between the area affected by fournier's gangrene and the type of reconstructive surgery used. A study with 80 patients. Int Braz J Urol 2007;33:510-514.
8.
Ayan F, Sunamak O, Paksoy SM, Polat SS, As A, Sakoglu N, Cetinkale O, Sirin F: Fournier's gangrene: a retrospective clinical study on forty-one patients. ANZ J Surg 2005;75:1055-1058.
9.
Brown DR, Davis NL, Lepawsky M, Cunningham J, Kortbeek J: A multicenter review of the treatment of major truncal necrotizing infections with and without hyperbaric oxygen therapy. Am J Surg 1994;167:485-489.
10.
Pizzorno R, Bonini F, Donelli A, Stubinski R, Medica M, Carmignani G: Hyperbaric oxygen therapy in the treatment of fournier's disease in 11 male patients. J Urol 1997;158:837-840.
11.
Saffle JR, Morris SE, Edelman L: Fournier's gangrene: management at a regional burn center. J Burn Care Res 2008;29:196-203.
12.
Laor E, Palmer LS, Tolia BM, Reid RE, Winter HI: Outcome prediction in patients with Fournier's gangrene. J Urol 1995;154:89-92.
13.
Yeniyol CO, Suelozgen T, Arslan M, Ayder AR: Fournier's gangrene: experience with 25 patients and use of Fournier's gangrene severity index score. Urology 2004;64:218-222.
14.
Corcoran AT, Smaldone MC, Gibbons EP, Walsh TJ, Davies BJ: Validation of the Fournier's gangrene severity index in a large contemporary series. J Urol 2008;180:944-948.
15.
Lin E, Yang S, Chiu AW, Chow YC, Chen M, Lin WC, et al: Is Fournier's gangrene severity index useful for predicting outcome of Fournier's gangrene? Urol Int 2005;75:119-122.
16.
Kabay S, Yucel M, Yaylak F, Algin MC, Hacioglu A, Kabay B, et al: The clinical features of Fournier's gangrene and the predictivity of the Fournier's Gangrene Severity Index on the outcomes. Int Urol Nephrol 2008;40:997-1004.
17.
Unalp HR, Kamer E, Derici H, Atahan K, Balci U, Demirdoven C, et al: Fournier's gangrene: evaluation of 68 patients and analysis of prognostic variables. J Postgrad Med 2008;54:102-105.
18.
Tuncel A, Aydin O, Tekdogan U, Nalcacioglu V, Capar Y, Atan A: Fournier's gangrene: three years of experience with 20 patients and validity of the Fournier's gangrene severity index score. Eur Urol 2006;50:838-843.
19.
HCUP: Overview, Healthcare Cost and Utilization Project. Rockville, Agency for Healthcare Research and Quality, 2008.
20.
Sorensen MD, Krieger JN, Rivara FP, Broghammer JA, Klein MB, Mack CD, et al: Fournier's gangrene: population based epidemiology and outcomes. J Urol 2009;181:2120-2126.
21.
Health Care Financing Administration: The International Classification of Diseases, 9th Revision, Clinical Modification: ICD-9-CM, ed 7. Washington, US Deptartment of Health and Human Services, Public Health Service for Sale by the Supt. of Docs., U.S. G.P.O., 2007, p 2 v.
22.
Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
23.
de Groot V, Beckerman H, Lankhorst GJ, Bouter LM: How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 2003;56:221-229.
24.
Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS; Urologic Diseases in America Project: mortality increases when radical cystectomy is delayed more than 12 weeks: results from a surveillance, epidemiology, and end results-Medicare analysis. Cancer 2009;115:988-996.
25.
Needham DM, Scales DC, Laupacis A, Pronovost PJ: A systematic review of the Charlson comorbidity index using Canadian administrative databases: a perspective on risk adjustment in critical care research. J Crit Care 2005;20:12-19.
26.
US Census: Annual estimates of the population for the United States, regions, states and puerto rico: April 1, 2000 to July 1, 2007, Population Division, US Census Bureau, 2007.
27.
US Census Bureau UDoCEaSA: Census regions and divisions of the United States.
28.
Chowdhury PP, Balluz L, Murphy W, Wen XJ, Zhong Y, Okoro C, Bartoli B, Garvin B, Town M, Giles W, Mokdad A: Surveillance of certain health behaviors among states and selected local areas - United States, 2005. MMWR Surveill Summ 2007;56:1-160.
29.
O'Loughlin RE, Roberson A, Cieslak PR, Lynfield R, Gershman K, Craig A, Albanese BA, Farley MM, Barrett NL, Spina NL, Beall B, Harrison LH, Reingold A, Van Beneden C: The epidemiology of invasive group a streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007;45:853-862.
30.
Hollabaugh RS Jr, Dmochowski RR, Hickerson WL, Cox CE: Fournier's gangrene: therapeutic impact of hyperbaric oxygen. Plast Reconstr Surg 1998;101:94-100.
31.
Yaghan RJ, Al-Jaberi TM, Bani-Hani I: Fournier's gangrene: changing face of the disease. Dis Colon Rectum 2000;43:1300-1308.
32.
Hejase MJ, Simonin JE, Bihrle R, Coogan CL: Genital Fournier's gangrene: experience with 38 patients. Urology 1996;47:734-739.
33.
Laucks SS 2nd: Fournier's gangrene. Surg Clin North Am 1994;74:1339-1352.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.